Fiboflapon Sodium

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameFiboflapon Sodium
Drug Alias Name菲夫拉朋Fiboflapon非夫拉朋GSK-2190915GSK-2190915A +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5-lipoxygenase activating protein inhibitors
Targets5-lipoxygenase activating protein
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksKEGG